Dial-in Info for Investor Conference Call with International Stem Cell ($ISCO)

Stem cell-based biotechnology company International Stem Cell Corporation (ISCO-OTC) will hold a conference call to update investors on its business and financial results on Wednesday, March 19, 2014. The call will cover results for the year ended December 31, 2013.

To attend this investor update, use the following dial-in information:

For a replay of the call, use the following dial-in information (replay only available through April 2, 2014).

About ISCO

ISCO is focused on the therapeutic applications of hpSCs and the development and commercialization of cell-based research and cosmetic products. The Company's proprietary technology is based on the creation of stem cells through parthenogenesis, a form of asexual reproduction that involves the stimulation of a human oocyte (egg) to start the cell division process without actual fertilization. Since the eggs are not fertilized, no viable human embryo is created nor destroyed for the generation of ISCO’s hpSC lines. The Company believes that these therapeutic stem cells avoid the safety, economic, and ethical concerns inherent with existing stem cell technologies.

ISCO has focused its therapeutic efforts in three markets where cell therapy has been clinically proven, but where there is a shortage of safe cells or tissue: (1) Parkinson’s disease (PD); (2) inherited metabolic liver diseases; and (3) corneal blindness. ISCO is also developing a stem cell bank, UniStemCell™, and produces and markets specialized cells and growth media for therapeutic research through its subsidiary Lifeline Cell Technology, and stem cell-based skin care products through its subsidiary Lifeline Skin Care.